Hims & Hers Sells Zepbound and Foundayo, Moving Away From Compounded GLP-1s

Complete guide: GLP-1 drugs: a complete guide to semaglutide and beyond

The short version: on November 6, 2026, Eli Lilly and Hims & Hers announced a deal under which patients on the platform with a prescription from a licensed provider can buy Zepbound (tirzepatide) and Foundayo (orforglipron) at the same self-pay prices Lilly offers, without leaving Hims¹². For clinicians following the U.S. GLP-1 market, it is the clearest signal yet that the country's largest telehealth platform is moving away from mass compounding.

What Lilly and Hims & Hers announced

According to the Business Wire release, the process covers a consultation, a prescription if the provider judges it appropriate, and home shipment of the Lilly medicine¹. Before, according to pharmaphorum, those prescriptions were redirected to LillyDirect, Lilly's direct-to-consumer channel³. Hims adds 24/7 care team access, nutrition guidance and regular clinical check-ins for its weight loss members¹.

The release contains two commitments that matter for regulation. First, both companies committed to protecting independent clinical decision-making, so providers keep prescribing whatever treatment they judge right for each patient¹. Second, verbatim: "Hims & Hers has never offered access to compounded copies of Lilly's GLP-1s, and has committed not to do so in the future"¹.

The commercial weight of the channel is large: Lilly says self-pay accounts for approximately 40–45% of Zepbound sales⁴. Pharmaphorum adds that, with limited insurance coverage, these drugs are mostly bought out of pocket³. In the words of Ilya Yuffa, president of Lilly USA, Hims patients "now have a simple, more direct way to get FDA-approved Lilly medicine"¹. Hims co-founder and CEO Andrew Dudum called Lilly "one of the most innovative pharmaceutical companies in history"¹.

Clinically, neither product is new to the literature: weekly tirzepatide for obesity was published in the New England Journal of Medicine in 2022¹², and a report in the same journal describes orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity treatment¹³. The approved labels, not this note, are the reference for indications, contraindications and risks; Lilly's release reproduces the warnings for both¹.

How Hims got here: the February 2026 reversal

The Lilly deal only makes sense after February. On February 5, 2026, Hims & Hers launched a compounded oral semaglutide as an alternative to Novo Nordisk's Wegovy pill, advertised as having "the same active ingredient as Wegovy" but "not approved or evaluated for safety, effectiveness, or quality by the FDA"⁶. The next day the FDA announced its intent to take "decisive steps" to restrict GLP-1 active pharmaceutical ingredients (APIs) used in non-approved compounded drugs, and named Hims in its statement⁵. The same day, the HHS General Counsel said on social media that his office had referred the company to the Department of Justice for possible violations of federal law⁶.

On February 7, Hims announced: "we have decided to stop offering access to this treatment," after "constructive conversations with stakeholders across the industry"⁷. On February 9, Novo Nordisk filed a patent infringement suit over its semaglutide compound⁶. A month later, on March 9, Novo and Hims announced a deal: Hims would sell branded Ozempic and Wegovy (injectable and oral)⁸⁹. Novo agreed to drop the suit but keeps the right to refile it, and Hims would stop advertising compounded GLP-1s⁹. Novo CEO Mike Doustdar called it "a meaningful win for patients in the United States"⁸.

A note on precision: Lilly's wording about "compounded copies" refers to its own products. Hims did offer compounded semaglutide, which is Novo Nordisk's drug, until February, and Novo had ended an earlier partnership in 2025 saying Hims had "wrongfully marketed copycats" of Wegovy⁷.

What it means for 503A compounding

The FDA was explicit on February 6: it would use "all available compliance and enforcement tools," and warned that failing to address violations "may result in legal action without further notice, including, without limitation, seizure and injunction"⁵. Planned actions include restricting access to GLP-1 APIs for non-approved compounded drugs and curbing misleading advertising: promotional materials cannot present a compounded product as generic or the same as an approved drug⁵. Law firms analyzing the announcement note that its final form remains unclear⁶.

With this deal, the telehealth platform with the most volume reduces its exposure on that front: it is left with two branded manufacturers (Lilly and Novo Nordisk) as GLP-1 partners¹⁸. For 503A compounding pharmacies, which depend on prescription channels, that narrows one distribution route, a point one of them has already raised in court¹¹. For the clinician, the practical implication is documentation: when a patient brings a compounded GLP-1, record the source, the API and the pharmacy, because compounded product quality is heterogeneous. A pharmacovigilance review of compounded GLP-1 adverse events in FAERS¹⁷, a case series of compounded semaglutide administration errors reported to a poison control center¹⁴, an analysis of semaglutide products sold online without a prescription¹⁶ and a report of a novel impurity in mass-compounded tirzepatide/B12 products¹⁵ support that caution.

What it means for the wider peptide policy debate

The story does not end with GLP-1s. The FDA has sent warning letters to pharmacies that advertised GLP-1s as approved-drug "copies," a topic we covered in the Empower warning letter, and Lilly has taken clinics to court over retatrutide, which is not yet approved, as we explained in Lilly's suits against aesthetic clinics. The pattern repeats: regulators and brand manufacturers are hardening the line between the approved drug and the copy, and their tools (API restriction, advertising rules, patents) reach any peptide presented as an alternative to a branded drug.

There is also an argument about how far the rules should reach. A consumer group applauded the FDA's move: "Consumers deserve safe, proven medications — not copycat drugs dressed up by slick marketing"¹⁰. From the other side, a compounding pharmacy argues that manufacturers' alliances with telehealth platforms suppress competition, an argument we develop below¹¹.

What to check

• That the product the patient receives is the FDA-approved branded one and that its source is in the chart¹.
• That the prescription reflects the provider's clinical judgment, not an access program: both companies committed to protecting that independence¹.
• That no promotional material presents a compounded product as equivalent to an approved one, something the FDA said it will watch⁵.
• News on the API restriction and the Department of Justice referral: the sources reviewed show no public outcome as of this writing⁵⁶.

Bottom line

The November 6, 2026 deal does not settle the compounding dispute, but it shows where the market moves when regulator, manufacturer and platform all agree that mass copying is not sustainable. For clinicians the task is unchanged: prescribe on evidence, document the product's source and distinguish the approved from what is only sold as an alternative.